Oncology Mice Models Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global oncology mice models market continues its upward trajectory, poised to achieve a market value of US$ 410 million in 2024, with a projected growth rate of 8.0% over the coming decade. This growth is driven by the increasing demand for mice models in oncology and immune-oncology research, propelled by technological advancements and emerging opportunities in emerging economies.

Syngeneic Tumor Mice Models Lead the Charge

Syngeneic tumor mice models are anticipated to dominate the market, representing more than 50% of the total oncology mice models market. The prominence of syngeneic tumor mice models underscores their critical role in advancing oncology research and drug development.

Seizing Opportunities in Emerging Economies

The forecast period promises lucrative opportunities for suppliers of oncology mice models worldwide, particularly in emerging economies. Key players in the industry are strategically expanding their presence in these regions to capitalize on the growing demand for mice models in oncology studies. The consolidation of the industry by a few key players emphasizes the importance of strategic expansion into new markets.

Immuno-Oncology: Shaping the Future of Cancer Treatment

The landscape of immuno-oncology (IO) is rapidly evolving, presenting new avenues for research and drug development. With thousands of new IO drugs and combinations in the development pipeline, there is a pressing need for efficient preclinical evaluation techniques. Immune-oncology mice models play a pivotal role in facilitating the transition from preclinical to clinical evaluations, offering valuable insights into human biology and accelerating the development of innovative therapies.

Harnessing the Power of Humanized Mice Models

Pharmaceutical companies are increasingly turning to humanized mice models to gain insights from human biology during preclinical trials. Models such as NOG and NOD hold particular promise for such studies, offering a platform to bridge the gap between preclinical research and clinical applications. The development of humanized mice models presents a significant opportunity for Contract Research Organizations (CROs) to expand their market share and contribute to advancements in oncology research.

Challenges and Restraints

Despite the promising growth prospects, the oncology mice models market faces challenges from animal welfare organizations opposing the use of animals in preclinical trials. Advocates have called for the exploration of alternatives to animal testing, urging the reduction of animal usage and the refinement of experimental procedures to minimize pain and discomfort. Addressing these concerns while advancing research is imperative for sustained growth in the market.

Country-Wise Insights

United States: The U.S. emerges as the largest market for oncology and immune-oncology mice models, accounting for over 91% market share in North America. The presence of numerous contract research organizations conducting preclinical studies, coupled with ongoing advancements in mice model development, contributes to the country's dominant position in the market.

United Kingdom: With a 20% market share value in Europe, the U.K. is fast becoming a prominent market for oncology mice models. Research institutions such as the Cancer Research U.K. Beatson Institute and the University of Glasgow are driving market growth through their focus on developing targeted treatments for various cancers.

China: China exhibits significant growth potential, accounting for approximately 29.5% of the market revenue share in the APAC region. Government-funded initiatives and collaborations with international partners are fueling research efforts aimed at developing new cancer treatments, positioning China as a key market for industry participants.

Competitive Analysis

Leading companies in the oncology mice models market are committed to providing a diverse range of models to support preclinical trials in oncology and immuno-oncology. Key players are actively engaged in product launches, acquisitions, and expansions to strengthen their market presence and meet the evolving demands of researchers worldwide.

Key Companies Profiled Include:

The Jackson Laboratory
Charles River
Taconic
Shanghai Model Organism
Envigo
Biocytogen
Cyagen
Genoway
Applied Stem Cells
Ingenious Targeting Labs
PolyGene
Creative Biolabs
TransCure Bioservices
Champions Oncology
Certis Oncology
Sygnature Discovery
Pharmaron
Labcorp
GemPharmatech
Janvier Labs
Harbour Biomed
Crown Bioscience Inc. (JSR Corporation)

Key Segments Covered in Oncology Mice Models Industry Research

Oncology Mice Models Market by Product:

Humanized Immune System Mice Models
Syngeneic Tumor Mice Models
Immunodeficient Mice Models
NOG Mice Models
Spontaneous Tumor Mice Models
Others

Oncology Mice Models Market by End User:

Contract Research Organizations
Pharma and Biopharma Companies
Academic and Research Institutes

Oncology Mice Models Market by Region:

North America Oncology Mice Models Market
Latin America Oncology Mice Models Market
Europe Oncology Mice Models Market
Asia Pacific Oncology Mice Models Market
Middle East and Africa (MEA) Oncology Mice Models Market

1. Executive Summary

1.1. Global Oncology Mice Models Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Oncology Mice Models Market Outlook, 2018 - 2031

3.1. Global Oncology Mice Models Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Humanized Immune System Mice Models
  - 3.1.1.2. Syngeneic Tumor Mice Models
  - 3.1.1.3. Immunodeficient Mice Models
  - 3.1.1.4. NOG Mice Models
  - 3.1.1.5. Spontaneous Tumor Mice Models
  - 3.1.1.6. Others
3.2. Global Oncology Mice Models Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Contract Research Organizations
  - 3.2.1.2. Pharma and Biopharma Companies
  - 3.2.1.3. Academic and Research Institutes
3.3. Global Oncology Mice Models Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Oncology Mice Models Market Outlook, 2018 - 2031

4.1. North America Oncology Mice Models Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Humanized Immune System Mice Models
  - 4.1.1.2. Syngeneic Tumor Mice Models
  - 4.1.1.3. Immunodeficient Mice Models
  - 4.1.1.4. NOG Mice Models
  - 4.1.1.5. Spontaneous Tumor Mice Models
  - 4.1.1.6. Others
4.2. North America Oncology Mice Models Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Contract Research Organizations
  - 4.2.1.2. Pharma and Biopharma Companies
  - 4.2.1.3. Academic and Research Institutes
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Oncology Mice Models Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 4.3.1.2. U.S. Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 4.3.1.3. Canada Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 4.3.1.4. Canada Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Oncology Mice Models Market Outlook, 2018 - 2031

5.1. Europe Oncology Mice Models Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Humanized Immune System Mice Models
  - 5.1.1.2. Syngeneic Tumor Mice Models
  - 5.1.1.3. Immunodeficient Mice Models
  - 5.1.1.4. NOG Mice Models
  - 5.1.1.5. Spontaneous Tumor Mice Models
  - 5.1.1.6. Others
5.2. Europe Oncology Mice Models Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Contract Research Organizations
  - 5.2.1.2. Pharma and Biopharma Companies
  - 5.2.1.3. Academic and Research Institutes
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Oncology Mice Models Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.3.1.2. Germany Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.3.1.3. U.K. Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.3.1.4. U.K. Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.3.1.5. France Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.3.1.6. France Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.3.1.7. Italy Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.3.1.8. Italy Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.3.1.9. Turkey Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.3.1.10. Turkey Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.3.1.11. Russia Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.3.1.12. Russia Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Oncology Mice Models Market Outlook, 2018 - 2031

6.1. Asia Pacific Oncology Mice Models Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Humanized Immune System Mice Models
  - 6.1.1.2. Syngeneic Tumor Mice Models
  - 6.1.1.3. Immunodeficient Mice Models
  - 6.1.1.4. NOG Mice Models
  - 6.1.1.5. Spontaneous Tumor Mice Models
  - 6.1.1.6. Others
6.2. Asia Pacific Oncology Mice Models Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Contract Research Organizations
  - 6.2.1.2. Pharma and Biopharma Companies
  - 6.2.1.3. Academic and Research Institutes
- 6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Oncology Mice Models Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.3.1.2. China Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.3.1.3. Japan Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.3.1.4. Japan Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.3.1.5. South Korea Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.3.1.6. South Korea Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.3.1.7. India Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.3.1.8. India Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Oncology Mice Models Market Outlook, 2018 - 2031

7.1. Latin America Oncology Mice Models Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Humanized Immune System Mice Models
  - 7.1.1.2. Syngeneic Tumor Mice Models
  - 7.1.1.3. Immunodeficient Mice Models
  - 7.1.1.4. NOG Mice Models
  - 7.1.1.5. Spontaneous Tumor Mice Models
  - 7.1.1.6. Others
7.2. Latin America Oncology Mice Models Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Contract Research Organizations
  - 7.2.1.2. Pharma and Biopharma Companies
  - 7.2.1.3. Academic and Research Institutes
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Oncology Mice Models Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.3.1.2. Brazil Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.3.1.3. Mexico Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.3.1.4. Mexico Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.3.1.5. Argentina Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.3.1.6. Argentina Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Oncology Mice Models Market Outlook, 2018 - 2031

8.1. Middle East & Africa Oncology Mice Models Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Humanized Immune System Mice Models
  - 8.1.1.2. Syngeneic Tumor Mice Models
  - 8.1.1.3. Immunodeficient Mice Models
  - 8.1.1.4. NOG Mice Models
  - 8.1.1.5. Spontaneous Tumor Mice Models
  - 8.1.1.6. Others
8.2. Middle East & Africa Oncology Mice Models Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Contract Research Organizations
  - 8.2.1.2. Pharma and Biopharma Companies
  - 8.2.1.3. Academic and Research Institutes
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Oncology Mice Models Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.3.1.2. GCC Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.3.1.3. South Africa Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.3.1.4. South Africa Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.3.1.5. Egypt Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.3.1.6. Egypt Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.3.1.7. Nigeria Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.3.1.8. Nigeria Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Oncology Mice Models Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Oncology Mice Models Market by End User, Value (US$ Mn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Product vs by End User Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. The Jackson Laboratory
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Therapy Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Charles River
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Therapy Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Taconic
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Therapy Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Shanghai Model organism
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Therapy Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Envigo
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Therapy Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Biocytogen
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Therapy Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Cyagen
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Therapy Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Genoway
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Therapy Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Applied stem cells
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Therapy Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Ingenious targeting labs
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Therapy Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. PolyGene - Transgenic mice model company
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Therapy Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Creative Biolabs
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Therapy Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. TransCure Bioservices
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Therapy Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development
- 9.4.14. Champions oncology
  - 9.4.14.1. Company Overview
  - 9.4.14.2. Therapy Portfolio
  - 9.4.14.3. Financial Overview
  - 9.4.14.4. Business Strategies and Development
- 9.4.15. Certis oncology
  - 9.4.15.1. Company Overview
  - 9.4.15.2. Therapy Portfolio
  - 9.4.15.3. Financial Overview
  - 9.4.15.4. Business Strategies and Development
9.5. Research Methodology
9.6. Report Assumptions
9.7. Acronyms and Abbreviations